Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Exenatide 10 ug subcutaneous twice daily Exenatide twice daily	oral glucose lowering drugs except sulfonylureas and nateglinide; lifestyle: standard	33	27
A2	Premixed insulin Insulin aspart 70/30	oral glucose lowering drugs except sulfonylureas and nateglinide; lifestyle: standard	33	32

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Exenatide 10 ug subcutaneous twice daily A1	Premixed insulin A2
age	mean (years)	58.85	58.03
age	sd (years)	12.54	13.32
bmi	mean (kg/m2)	23.64	24.36
bmi	sd (kg/m2)	2.86	2.52
diabetes duration	mean (years)	6.59	7.81
diabetes duration	sd (years)	5.32	6.02
female	n	8	18
hba1c	mean (percent)	8.67	8.32
hba1c	sd (percent)	1.03	0.96
sbp	mean (mmHg)	127.03	125.46
sbp	sd (mmHg)	16.48	15.04
weight	mean (kg)	68.68	66.30
weight	sd (kg)	11.95	11.42

Analyses this trial contributes to

HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); network meta-analysis
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); network meta-analysis
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); pairwise meta-analysis
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); network meta-analysis
Level 2 or 3 hypoglycemia (participants)
Type 2 diabetes (adults); longest follow-up; network meta-analysis
Level 2 or 3 hypoglycemia (participants)
Type 2 diabetes (adults); longest follow-up; network meta-analysis
Level 2 or 3 hypoglycemia (participants)
Type 2 diabetes (adults); longest follow-up; network meta-analysis
Level 2 or 3 hypoglycemia (participants)
Type 2 diabetes (adults); longest follow-up; network meta-analysis
Systolic blood pressure change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); network meta-analysis
Systolic blood pressure change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); network meta-analysis

Results

11 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

HbA1c change (2 lines; O01)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
52	A1	change	-1.31 percent	1.42		27	not stated; full analysis; R0018574:Table 2
52	A2	change	-1.09 percent	1.42		32	not stated; full analysis; R0018574:Table 2

Body weight change in kilograms (diabetes) (2 lines; O02)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
52	A1	change	-2.21 kg	3.43		27	not stated; full analysis; R0018574:Table 2
52	A2	change	1.57 kg	2.96		32	not stated; full analysis; R0018574:Table 2

Level 2 or 3 hypoglycemia (participants) (4 lines; O04)

Arm	Statistic	Events / N	Detail
A1	events	1 / 27	not stated; full analysis; R0018574:Results
A1	events	0 / 27	not stated; full analysis; R0018574:Results
A2	events	0 / 32	not stated; full analysis; R0018574:Results
A2	events	5 / 32	not stated; full analysis; R0018574:Results

Systolic blood pressure change (2 lines; O05)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
52	A1	change	-1.85 mmHg	14.35		27	not stated; full analysis; R0018574:Table 2
52	A2	change	2.25 mmHg	18.74		32	not stated; full analysis; R0018574:Table 2

Discontinuation due to adverse events (1 lines; O26)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				1 / 33	not stated; randomized; R0018574:Figure 1

S003030

Design

Conduct and analysis

Arms

Baseline characteristics

Analyses this trial contributes to

Results